Health ProductsDear Healthcare Professional Letter

Avastin (bevacizumab) - Health Canada has Suspended Approval for Use in Metastatic Breast Cancer - For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Biologic/vaccine
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Introduction

This is duplicated text of a letter from Hoffmann-La Roche Ltd.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Details

Health Canada Endorsed Important Safety Information on Avastin (bevacizumab)

November 29, 2011

Subject: Health Canada has suspended approval of Avastin® (bevacizumab) for use in metastatic breast cancer

Dear Health Care Professional,

This letter is to inform you that on November 25, 2011 Health Canada made a final decision to suspend the NOC/c for AVASTIN in combination with paclitaxel for treatment of patients with metastatic breast cancer (mBC).

This action is specific to AVASTIN's breast cancer indication and does not impact AVASTIN's approved uses for other cancer types in Canada.

As such, the current Product Monograph for AVASTIN, dated September 2, 2011, will be updated shortly to reflect the suspension of the metastatic breast cancer indication, including the removal of any reference to clinical trials in mBC.

The revised AVASTIN Product Monograph is not yet available, but as soon as it is revised and approved by Health Canada, it will be posted on our website: Roche Canada

Should you have any questions or require additional information regarding the use of AVASTIN, please contact the Drug Information Department at Hoffmann-La Roche Limited at 1-888-762-4388, Monday to Friday, between 8:30 a.m. and 4:30 p.m. (Eastern Standard Time),

Hoffmann-La Roche Ltd.
Telephone: 1-888-762-4388

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

  • Report online at MedEffect™ Canada
  • Call toll-free at 1-866-234-2345
  • Complete a Reporting Form and:
    • Fax toll-free to 1-866-678-6789, or
    • Mail to: Canada Vigilance Program
      Health Canada
      Postal Locator 0701E
      K1A 0K9

The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.

For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738

To change your mailing address or fax number, contact the Market Authorization Holder (Industry).

Sincerely,

Hoffmann-La Roche Limited

original signed by

Lorenzo Biondi
Vice President,
Medical and Regulatory Affairs

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime